Medicamen Biotech Limited has informed the Exchange regarding Board meeting held on April 24, 2025 for allotment of 8,48,220 Equity Shares and 6,50,000 Fully convertible warrants
MEDICAMEQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.9 pts more than Nifty Microcap 250 and 1.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Medicamen Biotech's Board of Directors met on April 24, 2025 and approved the allotment of 8,48,220 equity shares along with 6,50,000 fully convertible warrants. The warrants, once exercised, will convert into additional equity shares of the company, effectively increasing the share capital in two stages. This indicates a fundraising exercise, most likely through preferential allotment or a private placement to specific investors or promoters. No pricing details, conversion ratio, or allottees have been disclosed in this filing. The total potential dilution from full conversion of warrants will be significant relative to typical small-cap shareholding patterns.
Existing shareholders will see their ownership stake diluted both immediately (through the equity share allotment) and potentially again in the future (when warrants are converted). The move signals capital infusion into the company, but without clarity on pricing or use of proceeds, investors should watch for follow-up disclosures to assess whether the funds are being raised at fair value.